Showing studies matching your search1 results shown

Studies (1 shown)

NCT05301842PHASE3ACTIVE_NOT_RECRUITING

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

Sponsor · AstraZenecaCondition · Hepatocellular CarcinomaIntervention · Tremelimumab, DurvalumabUpdated Apr 2026
Showing top 1 results. See all 1 results on CT.gov →